Press Releases OSE Immunotherapeutics

Equities

OSE

FR0012127173

Market Closed - Euronext Paris Other stock markets 11:35:28 2024-04-26 am EDT			5-day change	1st Jan Change
5.56 ^EUR	-0.71%		+3.35%	+29.91%

Apr. 17	OSE: licensing agreement with AbbVie enters into force	CF
Apr. 17	OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OSE Immunotherapeutics Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	Apr. 17	AQ
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective	Apr. 16	GL
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer	Apr. 10	GL
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer	Apr. 10	AQ
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology	Apr. 02	GL
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update	Mar. 27	BU
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update	Mar. 27	GL
OSE Immunotherapeutics : Inside Information / Other news releases	Mar. 18	PU
OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis	Mar. 18	BU
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation	Feb. 29	AQ
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook	Jan. 22	AQ
OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase Study Evaluating FR104/VEL-101 Immunotherapy in Renal transplant	Dec. 12	AQ
Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023	Nov. 30	AQ
OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi	Nov. 22	AQ
OSE Immunotherapeutics presents the first positive clinical results of its anti-PD1 monoclonal antibody OSE-279 evaluated in advanced solid tumors	23-10-17	AQ
OSE Immunotherapeutics Updates on its Research Programs in Presentations Selected for Upcoming International Conferences International CICON Conference SITC Annual Meeting PEGS Europe Summit	23-09-21	AQ
OSE Immunotherapeutics Announces, Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology	23-09-12	AQ
OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics	23-08-02	AQ
OSE Immunotherapeutics : 02/08/2023 OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics	23-08-01	PU
OSE Immunotherapeutics : 2023 2022 Universal registration document	23-07-25	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OSE Immunotherapeutics

Equities

OSE

FR0012127173

Press Releases

Filters